OncoCyte Corporation (OCX)
Company Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| IPO Date | Dec 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California United States | |
| Website | https://oncocyte.com |
Stock Details
| Ticker Symbol | OCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C107 |
| ISIN Number | US68235C2061 |
| Employer ID | 27-1041563 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer & Director |
| Andrea Susan James | Chief Financial Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Dr. Paul R. Billings FACP, M.D. | Consulting Chief Medical Officer |
| James Liu | Vice President of Accounting, Treasurer, Senior Director, Controller & Principal Accounting Officer |
| Peter Hong | Vice President, General Counsel & Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 8-K | Current Report |
| Apr 08, 2025 | 424B3 | Filing |
| Mar 28, 2025 | S-1 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 24, 2025 | 10-K | Annual Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 04, 2025 | SCHEDULE 13G/A | [Amend] Filing |